Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy

Leuk Lymphoma. 2024 Jun;65(6):864-867. doi: 10.1080/10428194.2024.2324991. Epub 2024 Mar 5.

Affiliations

¹ Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
² Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA.

PMID: 38441062
DOI: 10.1080/10428194.2024.2324991

No abstract available

Keywords: AML; MDS; Venetoclax; magrolimab; myeloid.

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic* / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
CD47 Antigen* / antagonists & inhibitors
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Sulfonamides* / administration & dosage
Sulfonamides* / therapeutic use
Treatment Outcome

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
CD47 Antigen